Aurora Cannabis Faces Hostile Takeover: What It Means for Investors
Aurora Cannabis is confronted with a hostile takeover bid from Curaleaf, raising questions about the future of the North American cannabis sector.
Amylyx Pharmaceuticals' 55% Surge: A Turning Point for Avexitide and Biotech Investors
Amylyx Pharmaceuticals saw a 55% surge following positive results from its avexitide trial, signalin…
Moderna's Historic Phase 3 Cancer Vaccine Triumph: What Investors Need to Know
Moderna's stock saw a significant surge following its Phase 3 cancer vaccine success, indicating a p…
Curaleaf's Hostile Takeover Bid: A Game Changer for the Cannabis Industry
Curaleaf's $4/share bid for Aurora Cannabis could reshape the cannabis landscape, creating ripples a…
Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors
Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and …
BioMarin's Strategic Acquisition: What It Means for Investors
BioMarin's $275M acquisition of Alesta Therapeutics could enhance its rare disease focus and shareho…
30-Year Treasury Yield at 19-Year High: What It Means for US and Canadian Markets
The 30-year US Treasury yield has hit a 19-year high, reshaping market landscapes and investor strat…
Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors
Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting …
Amylyx Pharmaceuticals' Avexitide Phase 3 Success: What Investors Need to Know
Amylyx's Phase 3 success with avexitide shows promise for investors, especially amid past setbacks.
Nvidia's Strategic Move: Financing OpenAI's Data Center in Ohio
Nvidia's financing of OpenAI's data center marks a pivotal moment in AI infrastructure and investor …